UMass Medical University researchers to assess treatment solutions for early COVID-19 infection
UMass Medical College is collaborating in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Demo, which is becoming led by the AIDS Medical Trials Team (ACTG). ACTIV-2 features the two Stage II and Phase III evaluations of investigational brokers for treating early COVID-19. To qualify for ACTIV-2, individuals need to have analyzed positive for SARS-CoV-2 […]
Continue Reading